EUCTR2019-003466-41-DK进行中（未招募）1 期
In vivo molecular imaging of angiogenesis in type 2 diabetes
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET0 个研究点目标入组 90 人开始时间: 2019年8月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent must be provided before participation
- •Previous participation in the ”Kardiovaskulær risikoprofil hos personer med og uden type 2 diabetes vurderet med hjerte 82Rb-PET - Projekt-ID H-3-2013-015” study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Pregnancy or breastfeeding (urine HCG is performed on all fertile women)
- •Myocardial infarction = 30 days before inclusion
- •Percutaneous coronary intervention = 4 weeks before inclusion
- •Coronary artery bypass graft = 8 weeks before inclusion
- •Heart transplantation
- •Unstable angina
- •Known severe heart failure (LVEF < 35 %)
- •Known moderate-severe heart valve disease
- •Known severe hypertrophy of left ventricle
- •Uncontrolled arrhythmia, 2. or 3. degree AV-block or sick sinus syndrome - assessed from a standard 12-lead electrocardiogram
- •Systolic blood pressure < 90 or > 200 mmHg
- •Chronic obstructive pulmonary disease or asthma, defined as requirement of daily medical treatment
研究者
相似试验
进行中（未招募）
1 期
In vivo molecular imaging of angiogenesis after VEGF-D gene therapyIschemic heart diseaseMedDRA version: 20.0Level: LLTClassification code 10023024Term: Ischaemic heart diseaseSystem Organ Class: 100000004849EUCTR2018-001494-24-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET30
进行中（未招募）
1 期
Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients.MedDRA version: 20.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersAge-related macular degenerationEUCTR2019-000946-37-FRAssistance Publique-Hôpitaux de Marseille20
进行中（未招募）
1 期
PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)MedDRA version: 20.0Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10078184Term: Neuroendocrine tumor of the lung metastaticSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10078183Term: Neuroendocrine tumor of the lungSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10077560Term: Gastroenteropancreatic neuroendocrine tumor diseaseSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 100000004864EUCTR2017-002512-14-DKRigshospitalet120
进行中（未招募）
不适用
ANGIOGENESIS IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS) IN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH BEVACIZUMAB - IRST 153.02Patients affected by advanced colorectal carcinomaMedDRA version: 9.1Level: SOCClassification code 10017947EUCTR2010-021248-16-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
已完成
不适用
The role of (micro)vasculature and angiogenesis in inflammatory diseases of the human skipsoriasisred scaly skin disease10014982NL-OMON40712Dermatologie60